BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Genexine's GX-E4 Phase 3 trial shows non-inferiority to Mircera for anemia treatment, presented at WCN2023

Kidneys are responsible for 90% of the EPO produced in our bodies. CKD-induced anemia is caused by the failure to produce EPO (erythropoietin) due to long-...

April 12, 2023 | News

Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.

XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a P...

April 10, 2023 | News

First patient dosed in China Phase III trial for COPD, announces Nuance Pharma

Ensifentrine is a first-in-class, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and non-s...

April 07, 2023 | News

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

"BSI-045B is a next generation anti-TSLP mAb with high affinity and bioactivity that has the potential to offer greater therapeutic potential for patients ...

April 05, 2023 | News

Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management

Suvoda LLC in March month, launched a refreshed brand, to better reflect its leadership position as a global clinical trial technology company t...

April 04, 2023 | News

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

LNK01003 is an oral small molecule JAK inhibitor with intestine-restricted properties developed by the company for the treatment of ulcerative colitis and ...

April 04, 2023 | News

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model

According to the company's explanation, bacteriophages have been mainly used for R&D on bacterial infectious diseases, but recently the scope of applic...

April 04, 2023 | News

Ablaze Pharmaceuticals to Develop GPC3 Targeted Therapy for Liver Cancer in China

The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...

March 31, 2023 | News

ImmVira's MVR-C5252 for Malignant Glioma Approved for Clinical Trial in China

In July 2022, the Company entered into a cooperative agreement with China Resource Biopharma ("CRBio") to jointly develop MVR-C5252 in the Greate...

March 30, 2023 | Regulatory

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small mole...

March 30, 2023 | Regulatory

Kintor Pharma Completes Enrollment for KX-826 Phase III Trial for Male Androgenetic Alopecia in China

The Phase III clinical trial is a randomized, double-blind, placebo-controlled, multi-regional study designed to evaluate the efficacy and safety of 5mg (0...

March 29, 2023 | News

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antig...

March 29, 2023 | News

YS Biopharma's PIKA COVID-19 Vaccine Shows Better Antibody Response Than Inactivated Vaccine in Phase II Study

The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing a...

March 28, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

March 27, 2023 | News

Stay Connected